Nedsat nyrefunktion Hos patienter med let, moderat eller svært nedsat nyrefunktion var den systemiske eksponering for vildagliptin øget (Cmax 8- 66%, AUC 32- 134%), og den totale body- clearance var reduceret sammenlignet med forsøgspersoner med normal nyrefunktion.
Renal impairment In subjects with mild, moderate, or severe renal impairment, systemic exposure to vildagliptin was increased (Cmax 8-66%; AUC 32-134%) and total body clearance was reduced compared to subjects with normal renal function.